20th Dec 2006 07:00
Australian Federal Court Upholds Basic Lipitor Patent, Preventing Launch of Generic Ranbaxy Product Lipitor Protected from Generic Competition in Australia until 2012
NEW YORK, Dec. 20 - Pfizer Inc said today that the Australian Federal Court in Victoria has upheld the exclusivity of its basic patent covering atorvastatin, the active ingredient in Lipitor. The ruling, the culmination of a lawsuit filed in 2005 by generic drug manufacturer Ranbaxy, includes an injunction against Ranbaxy's product and preserves Lipitor's patent coverage in Australia through May 2012. Ranbaxy can appeal the decision.
The court found that a proposed Ranbaxy generic product would infringe Pfizer's basic Lipitor patent (AU 601,981). A second patent covering the calcium salt of atorvastatin (AU 628,198), which expires in September 2012, was ruled invalid by the court. Pfizer will appeal that ruling.
The Australian decision will not impact ongoing Lipitor patent actions in other countries. Pfizer said it will continue to vigorously defend against challenges to its intellectual property, noting that patents provide the necessary incentive to invest in new and life-saving medicines that benefit millions of patients globally.
SOURCE Pfizer Inc
12/20/2006
/CONTACT: Bryant Haskins, +1-212-733-8719/
/Photo: A free corporate logo to accompany this story is available immediately via Wieck Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call 972-392-0888/
/Web site: http://www.pfizer.com /
(PFE)
PFIZER INCRelated Shares:
PFZ.L